Molecular Partners 관리

관리 기준 확인 2/4

Molecular Partners CEO는 Patrick Amstutz, Jan2004 에 임명되었습니다 의 임기는 20.83 년입니다. 총 연간 보상은 CHF 1.05M, 36.8% 로 구성됩니다. 36.8% 급여 및 63.2% 보너스(회사 주식 및 옵션 포함). 는 CHF 3.54M 가치에 해당하는 회사 주식의 1.99% 직접 소유합니다. 3.54M. 경영진과 이사회의 평균 재임 기간은 각각 3.3 년과 4.6 년입니다.

주요 정보

Patrick Amstutz

최고 경영자

CHF 1.0m

총 보상

CEO 급여 비율	36.8%
CEO 임기	20.8yrs
CEO 소유권	2.0%
경영진 평균 재임 기간	3.3yrs
이사회 평균 재임 기간	4.6yrs

최근 관리 업데이트

We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Apr 11

Recent updates

We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

Sep 10

We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Apr 11

Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?

Jan 09

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Sep 08

Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023

Jun 23

What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today

Aug 31

Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

May 09

Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts

Dec 26

We're Hopeful That Molecular Partners (VTX:MOLN) Will Use Its Cash Wisely

Jun 24

Molecular Partners AG (VTX:MOLN) Could Be Less Than A Year Away From Profitability

Mar 09

Analysts Just Made A Major Revision To Their Molecular Partners AG (VTX:MOLN) Revenue Forecasts

Feb 10

Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

Jan 21

How Much Of Molecular Partners AG (VTX:MOLN) Do Insiders Own?

Dec 17

CEO 보상 분석

Patrick Amstutz 의 보수는 Molecular Partners 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-CHF 63m
Jun 30 2024	n/a	n/a	-CHF 58m
Mar 31 2024	n/a	n/a	-CHF 59m
Dec 31 2023	CHF 1m	CHF 385k	-CHF 62m
Sep 30 2023	n/a	n/a	-CHF 60m
Jun 30 2023	n/a	n/a	-CHF 62m
Mar 31 2023	n/a	n/a	-CHF 50m
Dec 31 2022	CHF 1m	CHF 383k	CHF 118m
Sep 30 2022	n/a	n/a	CHF 117m
Jun 30 2022	n/a	n/a	CHF 118m
Mar 31 2022	n/a	n/a	CHF 106m
Dec 31 2021	CHF 1m	CHF 380k	-CHF 64m
Sep 30 2021	n/a	n/a	-CHF 67m
Jun 30 2021	n/a	n/a	-CHF 72m
Mar 31 2021	n/a	n/a	-CHF 66m
Dec 31 2020	CHF 1m	CHF 380k	-CHF 63m
Sep 30 2020	n/a	n/a	-CHF 53m
Jun 30 2020	n/a	n/a	-CHF 48m
Mar 31 2020	n/a	n/a	-CHF 43m
Dec 31 2019	CHF 930k	CHF 363k	-CHF 36m
Sep 30 2019	n/a	n/a	-CHF 37m
Jun 30 2019	n/a	n/a	-CHF 38m
Mar 31 2019	n/a	n/a	-CHF 38m
Dec 31 2018	CHF 909k	CHF 346k	-CHF 37m
Sep 30 2018	n/a	n/a	-CHF 27m
Jun 30 2018	n/a	n/a	-CHF 18m
Mar 31 2018	n/a	n/a	-CHF 24m
Dec 31 2017	CHF 885k	CHF 344k	-CHF 25m

보상 대 시장: Patrick 의 총 보상 ($USD 1.18M )은 Swiss 시장( $USD 832.67K ).

보상과 수익: 회사가 수익성이 없는 동안 Patrick 의 보상이 증가했습니다.

CEO

Patrick Amstutz (49 yo)

20.8yrs

테뉴어

CHF 1,047,000

보상

Dr. Patrick Amstutz, Ph.D. is a Co-Founder of Molecular Partners AG and has been its Chief Executive Officer since November 2016 and serves as its Member of Management Board since 2004. Dr. Amstutz serves...

리더십 팀

이름	위치	테뉴어	보상	소유권
Patrick Amstutz	Co-Founder	20.8yrs	CHF 1.05m	1.99% CHF 3.5m
Michael Stumpp	Co-Founder	20.8yrs	데이터 없음	2.08% CHF 3.7m
Robert Hendriks	Senior VP of Finance	5.3yrs	데이터 없음	데이터 없음
Alexander Zurcher	COO & Member of Management Board	2.3yrs	데이터 없음	0.070% CHF 123.8k
Renate Gloggner	Executive VP of People & Community and Member of Management Board	2.9yrs	데이터 없음	0.062% CHF 110.8k
Daniel Steiner	Senior Vice President of Research & Technology	3.7yrs	데이터 없음	데이터 없음
Seth Lewis	Senior Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Michael Pitzner	General Counsel	2yrs	데이터 없음	데이터 없음
Pamela Trail	Strategic Consultant	5.3yrs	데이터 없음	데이터 없음
Anne Goubier	Senior Vice President of Research & Early Development	2.8yrs	데이터 없음	데이터 없음
Philippe Legenne	Chief Medical Officer	1.3yrs	데이터 없음	데이터 없음

3.3yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: MOLN 의 관리팀은 경험 ( 3.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Patrick Amstutz	Co-Founder	7.1yrs	CHF 1.05m	1.99% CHF 3.5m
Steven H. Holtzman	Independent Non Executive Director	10.5yrs	CHF 135.00k	0.040% CHF 70.9k
William A. Burns	Independent Chairman of the Board	7.1yrs	CHF 295.00k	0.073% CHF 129.8k
Vito Palombella	Independent Director	4.6yrs	CHF 125.00k	0.0095% CHF 16.9k
Agnete Fredriksen	Independent Director	3.6yrs	CHF 125.00k	데이터 없음
Michael Vasconcelles	Independent Director	4.6yrs	CHF 135.00k	0.0095% CHF 16.9k
Sandip Kapadia	Independent Director	4.6yrs	CHF 130.00k	0.0095% CHF 16.9k
Dominik Hochli	Independent Director	3.6yrs	CHF 133.00k	데이터 없음

4.6yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: MOLN 의 이사회는 경험(평균 재직 기간 4.6 년)으로 간주됩니다.

Molecular Partners 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Insufficient new directors

We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Molecular Partners AG, Annual General Meeting, Apr 17, 2024

Molecular Partners AG Announces Executive Changes

High number of new directors

Molecular Partners AG, Annual General Meeting, Apr 04, 2023

Recent updates

Molecular Partners AG Presents Preclinical Proof-Of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Third quarter 2024 earnings released: CHF0.49 loss per share (vs CHF0.35 loss in 3Q 2023)

New minor risk - Shareholder dilution

Molecular Partners AG has completed a Follow-on Equity Offering in the amount of $20.000004 million.

Molecular Partners AG has filed a Follow-on Equity Offering in the amount of $20.000004 million.

We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

Consensus revenue estimates decrease by 62%, EPS upgraded

Second quarter 2024 earnings released: CHF0.46 loss per share (vs CHF0.49 loss in 2Q 2023)

Price target decreased by 9.7% to CHF9.35

Price target increased by 11% to CHF10.35

Molecular Partners Announces the Debut of their Lead Radio-Darpin Therapy (RDT) Candidate MP0712, Targeting DLL3

Molecular Partners AG Presents Positive Data from Completed Phase 1 Trial of MP0317 (FAP X CD40 DARPin) Monotherapy in Patients with Advanced Solid Tumors At ASCO 2024

First quarter 2024 earnings released: CHF0.34 loss per share (vs CHF0.45 loss in 1Q 2023)

Insufficient new directors

Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Consensus revenue estimates fall by 45%

We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Full year 2023 earnings released: CHF1.89 loss per share (vs CHF3.63 profit in FY 2022)

Molecular Partners AG to Report First Half, 2024 Results on Aug 26, 2024

Consensus revenue estimates fall by 29%

Molecular Partners AG, Annual General Meeting, Apr 17, 2024

Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?

Molecular Partners AG to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Molecular Partners AG Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory AML and AML/MDS At ASH Annual Meeting

Molecular Partners AG Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

New major risk - Share price stability

Molecular Partners Ag to Present Initial Data from Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory Aml and Aml/Mds At the 65Th Ash Annual Meeting and Exposition

Third quarter 2023 earnings released: CHF0.35 loss per share (vs CHF0.41 loss in 3Q 2022)

Consensus revenue estimates decrease by 40%

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Second quarter 2023 earnings released: CHF0.49 loss per share (vs CHF0.14 loss in 2Q 2022)

Molecular Partners AG Announces Executive Changes

Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023

Consensus revenue estimates fall by 12%

First quarter 2023 earnings released: CHF0.45 loss per share (vs CHF4.74 profit in 1Q 2022)

Consensus revenue estimates decrease by 73%, EPS upgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Molecular Partners Initiates Clinical Study of Trispecific Candidate Mp0533 for the Treatment of Acute Myeloid Leukemia

Molecular Partners AG Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML

Price target decreased to CHF12.87

High number of new directors

Molecular Partners AG Presents Positive Interim Safety and Mechanistic Data from Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors

Third quarter 2022 earnings released: CHF0.41 loss per share (vs CHF0.38 loss in 3Q 2021)

Molecular Partners AG Announces Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End

Investor sentiment improved over the past week

Consensus forecasts updated

What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today

Second quarter 2022 earnings released: CHF0.14 loss per share (vs CHF0.56 loss in 2Q 2021)

Price target increased to CHF30.57

Molecular Partners AG, Annual General Meeting, Apr 04, 2023

Johnson Fistel Files A Class Action Complain Against Molecular Partners AG

Molecular Partners AG Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARP in Antiviral for SARS-CoV-2

Price target increased to CHF30.57

Pomerantz Law Firm Announces the Filing of A Class Action Against Molecular Partners Ag and Certain Officers and Directors – Moln

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

Price target decreased to CHF26.83

High number of new directors

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Molecular Partners AG Announces Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of Covid-19

Price target increased to CHF27.58

Novartis and Molecular Partners Report Positive Topline Data from Phase 2 Study for ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19

Forecast to breakeven in 2022

Price target decreased to CHF25.00

Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts

Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies

Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients

Third quarter 2021 earnings released: CHF0.38 loss per share (vs CHF0.67 loss in 3Q 2020)